Italian antitrust authorities are suspecting drug giants Novartis and Roche of a cartel and have launched an investigation into the matter, according to reports. The Italian Competition Authority is looking into whether the companies colluded to keep a drug off the shelves to leave space for a more expensive drug. Reports say the companies worked to keep Avastin, a drug to tread wet age related macular degeneration, off shelves to promote Lucentis, a more expensive but approved drug. Two complaints over the matter were filed to authorities by a private healthcare association and the Italian Opthalmological Society. The two companies in question are based in Switzerland.
Featured News
Judge Sets March 2027 Trial in Paramount-WBD Merger Challenge
Aug 5, 2026 by
CPI
FTC Scrutinizes Proposed $3.5 Billion Veterinary Products Merger
Aug 4, 2026 by
CPI
Apple Seeks Court Order in AI Trade Secrets Dispute With OpenAI
Aug 4, 2026 by
CPI
Australian Competition Watchdog Accepts EnergyAustralia Undertaking Over Retail Rule Breach
Aug 4, 2026 by
CPI
South Korea Weighs Sweeping Antitrust Overhaul
Aug 4, 2026 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Antitrust Compliance
Jul 20, 2026 by
CPI
Your Antitrust Compliance Program: A Strong Voice in Your Defense
Jul 20, 2026 by
Joe Murphy
Antitrust Compliance for the AI Pricing Era
Jul 20, 2026 by
Alejandra Uria & Andre Geverola
Race to Report: Antitrust Leniency in the Whistleblower Era
Jul 20, 2026 by
Brian R. Faerstein & Nicole H. Sprinzen
Antitrust-By-Design: Competition Compliance in Digital Markets
Jul 20, 2026 by
Marcos Drummond Malvar, Gabriela Costa Carvalho Forsman & Luciana Mendes